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Abstract 
RNA interference holds tremendous potential as one of the most powerful therapeutic strategies. However, the prop-
erties of short interfering RNA (siRNA), such as hydrophilicity, negative charge, and instability in serum have limited 
its applications; therefore, significant efforts have been undertaken to improve its cellular uptake. Cell penetrating 
peptides have been utilized to deliver various biologically active molecules, such as proteins, liposomes, nanoparti-
cles, peptide nucleic acids, and recently small interfering RNAs. Here, we introduce a new cell penetrating peptide 
GL1(Ac-GLWRAWLWKAFLASNWRRLLRLLR-NH2) to improve the intracellular uptake of siRNA. This peptide consists of 
four tryptophan residues that facilitated its binding with the cell membrane, five arginine residues and one lysine 
residue which are positively charged at physiological pH, which induced the formation of peptide-siRNA complexes 
and enhanced the affinity of the peptide and cell membrane. Moreover, GL1 adopted helical secondary structure due 
to the altered distribution of polar and nonpolar residues in the sequence. In this study, we investigated the effect of 
peptide/siRNA molar ratio on the particle size, surface charge, secondary structure, and uptake efficiency. The results 
showed that GL1 formed stable complexes with siRNA mainly through electrostatic interaction and hydrophobic 
interaction, and the complexes displayed a spherical shape with the size of ~100 nm and positive surface charge. 
Utilizing the techniques of fluorescence microscopy and flow cytometry, the intracellular localization of Cy3-labeled 
GAPDH siRNA was visualized and the cellular uptake was quantified. It is worth noting that in the serum free environ-
ment, compared to Lipofectamine 2000, GL1 achieved higher cellular uptake of siRNA (~95%); in the presence of 
serum, GL1 retained the same level of siRNA cellular uptake (~84%) as Lipofectamine 2000. In addition, the viability of 
cells treated by GL1 in all studied molar ratios was >85%, which was significantly higher than that treated by Lipo-
fectamine 2000 (~70%). Taken together, the peptide GL1 demonstrated promise as a siRNA delivery system.
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Background
The discovery of RNA interference (RNAi) has changed 
the field of gene therapy. RNAi is a post-transcriptional 
gene silencing process that can specifically and potently 
knock down the expression of target genes both in vitro 
and in vivo [1, 2]. RNAi can be induced by short inter-
fering RNA (siRNA). siRNAs are double stranded RNA 
fragments with 21–23 nucleotides that are capable of 
inducing the cleavage of mRNAs with the complementary 
sequence [1–3]. It is currently accepted that RNAi is one 
of the most important strategies for sequence-specific 
gene silencing in basic research and a potentially pow-
erful therapeutic treatment for various human diseases 
[4, 5]. However, siRNA induced RNAi at cellular level is 
limited by its poor cellular uptake associated with low 
permeability of the cell membrane to RNA [6]. Thus, 
an effective and safe transport system to condense and 
deliver synthesized siRNA into cells is mandatory. Dur-
ing the last two decades, a new family of peptides known 
as cell-penetrating peptides (CPPs) were identified and 
thoroughly studied. CPPs present the ability to cross cel-
lular membranes by a remarkably low toxic process and 
to promote the cellular internalization of biomolecules 
such as peptides, proteins, nucleic acids, peptide nucleic 
acids (PNA), liposomes, and nanoparticles [7–10]. How-
ever, the efficacy of siRNA delivery mediated by CPPs 
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remains unsatisfactory, mainly due to the insufficient 
delivery efficiency, cytotoxicity, and/or sensitivity to the 
medium [6].
In order to increase the potency of such vectors, we 
designed a new peptide GL1. The following criteria were 
considered for the peptide design and its sequence con-
tains: (1) hydrophobic residues, such as tryptophan, to 
facilitate membrane binding owing to its strong prefer-
ence for the lipid membrane interfacial region [11]; (2) 
cationic residues, such as arginine and lysine, to assist 
the formation of peptide-siRNA complexes and peptide-
membrane interactions through electrostatic interaction 
and hydrogen bonding [11]; (3) altered distribution of 
the polar and nonpolar residues, to achieve better inter-
action with the cell membrane due to the formation of 
helical secondary structure [12]. The prevailing hypoth-
esis is that the cationic peptide GL1 electrostatically 
complexes with the anionic siRNA to produce a neutral 
or positively charged complex that has sufficient stability 
to allow intracellular delivery of siRNA. In this study, we 
investigated the physicochemical characteristics of GL1 
when interacting with siRNA and evaluated the effect 
of its physicochemical characteristics on siRNA deliv-
ery efficiency and cytotoxicity. Chinese hamster ovary 
(CHO-K1) cells are a cell line derived from the ovary of 
the Chinese hamster and often used in studies of genet-
ics, toxicity screening, and nutrition and gene expression 
because of its rapid growth rate. Thus, CHO-K1 was used 
as a model system to test the biological responses for 
siRNA delivery in this study.
Methods
Materials
The GL1 peptide (Ac-GLWRAWLWKAFLASNWRRL 
LRLLR-NH2) with a molecular weight of 3,123.8  g/mol, 
was synthesized by CanPeptide Inc. (Quebec, CA) with 
95% purity. Cy3-labeled GAPDH siRNA was purchased 
from Ambion (SilencerTM GAPDH siRNA kit). The 
siRNA targeting sequence for eGFP (GCGACGUAAACG 
GCCACAAGU) was purchased from Dharmacon. The 
sense sequence is GACGUAAACGGCCACAAGUUC 
and the antisense sequence is ACUUGUGGCCGUU 
UACGUCGC. The negative control siRNA used here was 
purchased from Ambion. The MTT (3-(4,5-dimethyl-
thiazol-2-yl)-2,5-diphenyltetrazolium bromide, a yellow 
tetrazole) assay kit was purchased from Sigma-Aldrich 
(Oakville, CA).
Cell line
Chinese hamster ovary (CHO-K1) cells were purchased 
from American Type Culture Collection (ATCC CCL-
61). The cells were cultured in F-12K medium (Thermo 
Scientific, Ottawa, Canada) with 10% fetal bovine serum 
(FBS) (Sigma-Aldrich, Oakville, Canada). The cells were 
incubated at 37°C in a humidified atmosphere with 5% 
CO2.
Preparation of GL1 and GL1‑siRNA complexes
The peptide in powder was dissolved in filtered RNase-free 
water at a concentration of 500 µM, vortexed for 5 s, and 
ultrasonically mixed for 5 min. This stock was diluted to 
the desired concentrations for experiments. GL1-siRNA 
complexes were formed by simply mixing GL1 solutions to 
siRNA solutions at desired concentrations and ratios, and 
incubated at room temperature for 20 min.
Gel electrophoresis
The GL1-siRNA complexes in RNase-free water were 
made with 300 ng of eGFP siRNA. The samples of siRNA 
alone and GL1-siRNA complexes at molar ratios (pep-
tide/siRNA) ranging from 1/1 to 80/1 were electro-
phoresed on a 1.2% wt/vol agarose gel in 1× TBE at 55 V 
for 1 h. The ethidium bromide-stained siRNA was visual-
ized on an ultraviolet transilluminator with a camera.
Isothermal titration calorimetry (ITC)
The isothermal titration calorimetry experiments were 
conducted using a Nano-ITC calorimeter (TA Instru-
ments). A 500  μM GL1 peptide solution and a 10  μM 
siRNA solution were both prepared in RNase-free water. 
All of the samples were degassed in a degassing station 
(TA Instruments) prior to the experiments. RNase-free 
water was placed in the ITC reference cell. For each titra-
tion, 2 μl of the peptide in a pipette rotating at 250 rpm 
was injected into the siRNA solution in the sample cell of 
the calorimeter, which was equilibrated to 25°C, with an 
interval of 300 s between injections. The heat of dilution 
was measured by titrating the GL1 solution into RNase-
free water and was later subtracted from the sample 
measurement. The data were analyzed using NanoAna-
lyze software v.3.1.2.
Size and zeta potential measurements
Particle size measurements were done with a Zetasizer 
Nano ZS (Malvern, United Kingdom) with transparent 
ZEN0040 disposable microcuvette cells (40  µl) at 25°C. 
The GL1-siRNA samples were prepared as mentioned 
above with a siRNA concentration of 100  nM. The zeta 
potentials were measured in a Clear DTS1070 zeta dip 
cell with the same machine. For zeta potential measure-
ment in serum conditions, GL1-siRNA complexes were 
freshly prepared and diluted 1:10 with F12K + 10% FBS. 
The complexes were incubated in a serum-supplemented 
medium for 10 min before the measurement.
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Scanning electron microscopy (SEM)
The GL1-siRNA complexes were imaged with a SEM to 
characterize their morphology. The samples were pre-
pared as mentioned in “Cellular uptake and localization 
of siRNA complexes” with a siRNA concentration of 
100 nM and a GL1 to siRNA molar ratio 40/1. After the 
sample was incubated for 20  min at room temperature, 
40  µl of the sample placed on conductive silicon wafer 
was allowed to dry at room temperature. The sample was 
coated with 10 nm-thick gold before imaging. The image 
was taken using a LEO FESEM 1530 field-emission SEM.
Circular dichroism (CD) spectroscopy
Spectra at 250–190  nm with a spectral resolution and 
pitch of 1  nm and scan speed of 200  nm/min were 
recorded using a J-810 spectropolarimeter (Jasco, USA). 
Increasing amounts of siRNA were added to the pep-
tide, which was at a fixed concentration of 30  μM, to 
obtain different molar ratios of the two compounds. 
After 20  min incubation, the samples were transferred 
into 1-mm long quartz cells and maintained at 25°C. 
The spectra presented here are the average of three 
measurements.
Fluorescence microscopy and fluorescence‑activated cell 
sorting (FACS)
CHO-K1 cells were seeded at a density of 50,000 cells per 
well and incubated for 24 h in a 24-well flat-bottom plate 
before treatment. The cells were incubated with GL1-
Cy3-labeled siRNA complexes at a molar ratio of 20/1 
in OPTI-MEM (Invitrogen) for 4 h. Thereafter, the cells 
were rinsed with phosphate buffered saline (PBS) and 
washed with heparin (10  U/ml). After, these cells were 
fixed with 500  μl of cold 4% PFA for 30  min and then 
washed twice with PBS. The nuclei were stained using 
a DAPI solution (Sigma-Aldrich, Oakville, CA, USA). 
Images were taken with an inverted fluorescence micro-
scope (Zeiss AxioObserver Z1, CA, USA) and analyzed 
using AxioVision software.
The uptake of Cy3-labeled siRNA into the CHO-K1 
cells was quantified with a BD FACSVantage SE Cell 
Sorter flow cytometry (BD Biosciences, United States). 
CHO-K1 cells were plated at a density of 50,000 cells 
per well and incubated for 24 h in a 24-well flat-bottom 
plate. The medium was replaced with GL1-siRNA com-
plexes and control samples in OPTI-MEM (Invitrogen) 
or F12-K supplemented with 10% FBS with a siRNA con-
centration of 100  nM. After 4  h of incubation, the cells 
were rinsed with phosphate buffered saline (PBS) and 
washed with heparin (10  U/ml). After, trypsin–EDTA 
was added to detach the cells from the plate. The cells 
were re-suspended in 4% paraformaldehyde (PFA) and 
ready for quantitative analysis.
In vitro gene silencing efficiency
CHO-K1 cells were seeded at 35,000 cells/well in 24-well 
plates and incubated for 24 h. Next, the cells were incu-
bated with various complex formulations in Opti-MEM 
at 37°C for 4  h. Then, the cells were incubated for an 
additional 48 h in complete culture medium with siRNA 
concentration of 50  nM. To determine the serum effect 
on gene silencing efficiency, the cells were directly incu-
bated with various complex formulations in complete 
culture medium for 52 h and then prepared for analysis.
For qRT-PCR analysis, the total RNA was extracted from 
the treated cells using the SV Total RNA Isolation System 
(Promega, CA, USA). A Nanodrop (Nanodrop spectro-
photometer ND-1000, Thermo Scientific, Ottawa, CA) 
was used to determine the RNA concentrations. The RNA 
samples were reverse-transcribed into cDNA using a Bio-
Rad iScript cDNA synthesis kit according to the manu-
facturer’s protocol. After the cDNA was synthesized, PCR 
was performed with Brilliant II fast SYBR Green QPCR 
Master Mix (Agilent Technologies, Wilmington, DE, USA) 
using an Mx3005P™ real time PCR System (Agilent Tech-
nologies). The sequences of the primers used for the mouse 
GAPDH gene are 5′-TTGCTGTTGAAGTCGCAGGA 
G-3′ and 5′-TGTGTCCGTCGTGGATCTGA-3′ (Sigma, 
Oakville, Ontario, Canada). Cyclophilin, a house-keep-
ing gene, was used as an internal control to normalize 
the GAPDH gene expression. Mouse cyclophilin mRNA 
amplified using the following primers: 5′-AGGGTTTCTC 
CACTTCGATCTTGC-3′ and 5′-AGATGGCACAGGAG 
GAAAGAGCAT-3′ (Sigma, Oakville, Ontario, CA, USA).
Cytotoxicity assay
The cytotoxicity of peptide-siRNA complexes was deter-
mined by the MTT assay. In brief, cells were seeded at 
5,000 cells/well in clear, flat-bottomed, 96-well plates 
(Costar) 24  h before treatment. After being washed, 
100 μl of Opti-MEM that contained peptide-siRNA com-
plexes at different molar ratios was added to the wells 
and incubated for 4  h. Thereafter, 50  μl of 30% serum 
containing medium was added, and the cytotoxicity of 
the relevant reagents was determined by the MTT assay 
after 48 h. The absorbance at 570 nm was read on a plate 
reader (FLUOstar OPTIMA, BMG, Germany). The back-
ground absorbance of the multiwell plates at 690  nm 
was determined and subtracted from the 570 nm meas-
urement. The results obtained from triplicate wells were 
averaged and normalized to the value obtained from the 
non-treated cells.
Statistical analysis
Results were expressed as mean values ± SD. Data were 
analyzed by two tailed T test and only p values <0.05 
were considered statistically significant.
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Results and discussion
Effect of peptide to siRNA molar ratio on complex 
formation
The ability of GL1 to interact with siRNA was investi-
gated by gel electrophoresis. Binding between peptide 
and siRNA prevented RNA from being stained by EtBr. 
As shown in Figure 1, as molar ratio increased, the inten-
sity of siRNA decreased sharply due to the formation of 
GL1-siRNA complexes. At molar ratio 10/1, the intensity 
of siRNA was significantly low. At a slightly higher molar 
ratio 15/1, no free siNRA was detected on the agarose 
gel. This result indicated that the minimal molar ratio 
for siRNA delivery was around 10/1. This direct binding 
between cationic peptide and anionic siRNA would be 
initiated via electrostatic interactions. The formation of 
GL1-siRNA complexes and the thermodynamic param-
eters associated with the binding between peptide and 
siRNA was further investigated using isothermal titra-
tion calorimetry by titrating the siRNA with GL1. The 
heat exchange during the titration of siRNA by GL1 (in 
RNase-free water) was detected by the machine and out-
put as raw data. By fitting the raw data (upper panel of 
Figure 2) to a single-site model (lower panel of Figure 2), 
the thermodynamic parameters during the interaction 
were obtained and listed in Table 1.
GL1 represents high affinity for siRNA with the dis-
sociation constant of 2.24E−7  M. The obtained molar 
stoichiometry was 7.16, which implied that 7.16  mol 
GL1 could condense 1  mol siRNA. Theoretically, 7  mol 
GL1 could condense 1  mol siRNA, since the GL1 pep-
tide contains six positively charged residues (Arginine 
and Lysine) and the siRNA molecule consists of 21 pairs 
of negatively charged nucleotides. The experimental data 
was consistent with the theoretical value. In the ITC 
experiment, due to the stirring throughout the titra-
tion process, peptide and siRNA could interact to its 
full extent. However, in the gel experiment, the peptide 
and siRNA solution was mixed first and then incubated 
for 20 min without further mixing. The difference in the 
experimental settings leads to the slight difference in the 
molar stoichiometry. With an enthalpy of −18.71 kJ/mol, 
ΔS of 64.56  J/(mol  K), and entropy of −19.24  kJ/mol, 
the binding was entropy-driven, but enthalpy was also 
a major factor. Moreover, through calculation using the 
equation ΔG = ΔH − TΔS, ΔG was −37.94 kJ/mol indi-
cating that the formation of GL1-siRNA complexes was a 
thermodynamically favored process [13, 14].
Particle size and zeta potential
Considering that particle size and zeta potential are 
important characteristics of delivery systems associated 
with the delivery efficiency [15], dynamic light scatter-
ing was applied to gain a view of the physicochemical 
Figure 1 Binding ability of siRNA to GL1 studied by agarose gel-shift 
assay The formed GL1-siRNA complexes, stained with ethidium bro-
mide, were investigated by electrophoresis on agarose gel (1.2% wt/
vol). siRNAs, targeting eGFP genes, were complexed with GL1 at a 
series of molar ratios from 1/1 to 80/1. Lane 1 was siRNA control, and 
lanes 2–8 indicated correlated molar ratios. The amount of siRNA was 
300 ng.
Figure 2 Calorimetric titration of siRNA with GL1 at 25°C in RNase-
free water at pH 6. a Corrected thermogram of calorimetric titration 
of siRNA with GL1. b Binding analysis of siRNA with GL1 by fitting 
the raw data with an independent model. GL1 concentration was 
500 μM and siRNA concentration was 10 μM.
Table 1 Thermodynamic parameters when titrating siRNA 
with GL1 in water
Ka (1/M) ΔH (kJ/mol) n Kd (M) ΔS (J/(mol K))
4.47 × 108 −18.71 7.16 2.24 × 10−7 64.56
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properties of GL1-siRNA complexes. It has been reported 
that 200 nm is the approximate limit for cellular uptake 
by macropinocytosis and nanoparticles larger than 
200 nm may hinder its cellular internalization [16, 17]. As 
shown in Figure 3a, particle sizes remained in the range 
of 80–100 nm, which fell in the range suitable for cellu-
lar uptake. Interestingly, at molar ratio 40/1, particle size 
slightly decreased. Previous studies prove that as molar/
charge ratio increased, stronger electrostatic repulsion 
between complexes occurs, leading to smaller nanopar-
ticles [18, 19]. The other possible reason is that excess 
peptides formed smaller nanoparticles, thus decreased 
the average size. It is generally accepted that nanoparti-
cles with positive surface charge induce uptake via elec-
trostatic interaction with the anionic cell membranes 
[20]. Figure 3b shows that at molar ratio 20/1 and 40/1, 
nanoparticles displayed positive surface charge and the 
absolute values increased at higher molar ratio due to the 
addition of more cationic peptides. This positive surface 
charge allows interaction of GL1-siRNA complexes with 
the polyanionic glycosaminoglycans on the cell surface 
[21]. However, in serum-containing media, GL1-siRNA 
complexes exhibited a negative surface charge, indicat-
ing that serum proteins interacted with the outer layer 
of the complex and induced a negative surface charge. 
This result suggests that in serum conditions the uptake 
of GL1-siRNA complexes may be mediated by scavenger 
receptors, which were involved in the cellular uptake of 
negatively charged macromolecules [22].
Morphology and secondary structure
Moreover, Figure 4a shows the morphology of the GL1-
siRNA complexes formed at molar ratio 40/1 observed 
under SEM. The SEM image shows that GL1 and siRNA 
form spherical nanoparticles with the size less than 
100  nm. As shown in Figure  4b, The CD-spectrum of 
GL1 is characterized by a maximum at 190 nm, a mini-
mum at 207 nm, and a slight shoulder at 220 nm which 
implies that GL1 adopts α-helical structure. Upon add-
ing siRNA to retain the peptide/siNRA molar ratio 10/1, 
GL1 CD-spectrum displayed a minimum at 210  nm, a 
maximum at 190  nm, a slight shoulder at 220  nm, and 
the absolute values of the minimum and maximum 
increased, which reveals that GL1 adopts a higher con-
tent of α-helical structure. Adding more siRNA to retain 
the peptide/siRNA molar ratio at 5/1, GL1 represented 
a similar CD-spectrum and the absolute values of the 
minimum and maximum further increased. Similar phe-
nomena have been reported for other CPPs [23] and this 
conformational change is due to the presence of anionic 
component, siRNA, which can screen the positive charge 
Figure 3 a The hydrodynamic diameter and b zeta potential of 
the GL1-siRNA complexes prepared in RNase free water at different 
molar ratios were measured by dynamic light scattering (DLS); c zeta 
potential of the GL1-siRNA complexes in serum-supplemented F12K 
media. The siRNA concentration was fixed at 100 nM. At different 
molar ratios, the amount of GL1 was adjusted. Results are expressed 
as mean ± standard deviation (n = 3).
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of arginine residues in one face of the helical structure, 
thus, forming a stable helical structure. This stable heli-
cal structure facilitates better interaction with cell mem-
branes and enhances cellular internalization [24].
Cellular uptake and localization of siRNA complexes
The cellular localization of siRNA was shown in Fig-
ure  5a. The siRNAs were localized in cytosol and to 
regions in close proximity to the nuclear membrane and 
were distributed in a non-homogeneous pattern at the 
periphery of the nucleus. Previous studies demonstrated 
that localization of siRNA [25], Dicer [26], and RNAi 
activity [27] was restricted to the cytoplasm and siRNA 
entry into living cells was localized to perinuclear regions 
[28]. Our data indicating that siRNA localization was 
perinuclear (Figure 5) was in consonance with the previ-
ous studies.
siRNA cellular uptake was quantified by FACS. As 
shown in Figure  5b, c, either with or without the pres-
ence of serum, siRNA alone represented almost no 
uptake in CHO-K1 cells, which also confirmed the limi-
tation of siRNA alone in cellular uptake. Without the 
presence of serum, peptide GL1 achieved 95% uptake of 
siRNA at molar ratio 20/1 and 40/1, which is higher than 
Lipofectamine 2000 (Lipo 87%), one of the most efficient 
and commercially available transfection reagents. Due to 
the serum effect, the uptake of siRNA decreased to 75% 
(molar ratio 20/1) and 84% (molar ratio 40/1). However, 
at molar ratio 40/1, GL1 still achieved the same level of 
uptake as Lipo with the presence of serum. However, 
with or without serum, GL1-siRNA treated cells exhib-
ited higher fluorescence intensity than Lipo and fluores-
cence intensity increased with the peptide/siRNA molar 
ratio. This result indicated that peptide GL1 could effec-
tively protect siRNA and efficiently deliver siRNA to cells 
even in the presence of serum.
Gene silencing efficiency in vitro
With or without serum, the GAPDH gene silencing effi-
ciency induced by GL1-siRNA complexes (MR 40/1) at 
the mRNA level was investigated using qRT-PCR. Lipo-
fectamine 2000 was used as a positive control. As shown 
in Figure  6, GL1-siRNA complexes at a molar ratio of 
40/1 achieved 58 and 47% gene silencing efficiency with 
and without serum respectively. This result indicated that 
GL1 could efficiently deliver siRNA to cells and induced 
the specific gene silencing. With serum, gene silencing 
efficiency of GL1-siRNA complexes decreased compared 
to that without serum, respectively. This trend was con-
sistent with the cellular uptake result. The Lipofectamine 
2000-siRNA complexes induced 80 and 74% GAPDH 
gene silencing with and without serum. The possible rea-
son that GL1-siRNA complexes did not achieve similar 
gene silencing efficiency was that the complexes were 
retained inside endosomes following endocytosis [29].
Cellular toxicity
For a CPP to be a functional vector, it must achieve high 
uptake efficiency and exhibit low levels of cytotoxicity. 
It is well documented that the molar ratio of the posi-
tive vector to negative nucleic acid cargo affects toxicity 
and higher molar ratios may cause higher toxicity [30]. 
As shown in Figure  7, siRNA alone was not toxic. At 
molar ratio 10/1, GL1-siRNA complexes and GL1 alone 
did not cause toxicity. At molar ratio ≥20/1, viability of 
cells treated either with GL1-siRNA complexes or GL1 
alone had a slight drop owing to relatively higher surface 
charge, but it was still above 85%. Moreover, Lipo alone 
and Lipo-siRNA complexes achieved lower cell viability 
~70%. Thus, peptide GL1 showed attractive characteris-
tics with regards to the criteria of cytotoxicity.
Here, an amphipathic, cationic peptide GL1 was 
designed and investigated. Structurally, GL1 has dis-
persed cationic amino acids along the sequence, which 
differs from the arginine rich peptide R9, R9-hLF, and 
Figure 4 a SEM image of GL1-siRNA complexes at molar ratio 40/1, 
siRNA concentration was 100 nM. b CD spectra of GL1 alone and 
GL1-siRNA at different molar ratios. GL1 concentration was fixed at 
30 μM and GL1-siRNA complexes were formulated at molar ratios of 
5/1 and 10/1.
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Tat [31]. The peptide MPG and MPG-like peptides con-
sist of a hydrophobic domain and a hydrophilic domain 
which contributes to their amphipathic property [32, 
33]; while PF6 and PF14 incorporated a stearyl moiety 
in their sequences to improve amphiphilicity. However, 
peptide GL1 has hydrophilic and hydrophobic amino 
acids dispersed along the sequence, which leads to its 
amphipathicity and helical secondary structure. Another 
significant difference of GL1 from the peptides men-
tioned above is that GL1 utilizes four tryptophan amino 
acids distributed along the sequence to enhance cellu-
lar uptake of GL1-siRNA complexes via strong peptide-
membrane interaction. Gel electrophoresis results show 
that GL1 can form complexes with siRNA and encap-
sulate all the free siRNA at molar ratio 15/1. However, 
hLF, R9, R9-hLF, Tat, TP10, PF6, and PF14 require much 
higher molar ratio, near 50/1 to encapsulate all the free 
siRNA [31]. The ITC data further proved that GL1 had 
a strong affinity with siRNA (Kd = 2.24E−7 M) and the 
interaction of GL1 with siRNA was thermodynamically 
Figure 5 a Fluorescence microscope image of GL1-siRNA complexes at molar ratio 40/1 (magnification 40×). The red fluorescence indicated Cy3 
labeled siRNA, blue fluorescence represented DAPI stained nuclei. The lower panel was non-treated cells, used as a control. b FACS results of cellular 
uptake of siRNA. *P value < 0.05, in a serum free environment, the uptake of siRNA at molar ratios of 20/1 and 40/1 is significantly different from 
that after Lipo treatment. **P value < 0.05, in a serum environment, the uptake of siRNA at a molar ratio of 20/1 is significantly different from that at 
a molar ratio of 40/1 and after Lipo treatment. c Relative fluorescent intensities at different treatment conditions. *P value < 0.05, the fluorescence 
intensity at molar ratios of 20/1 and 40/1 with or without serum is significantly different from that after the other treatments. Non-treated sample 
was negative control; Lipo-siRNA complexes were positive control. Cy3 labeled GAPDH siRNA was used here. siRNA concentration was 100 nM in 
both experiments. NT non-treated, MR peptide/siRNA molar ratio, Lipo Lipofectamine 2000. Results are expressed as mean ± standard deviation 
(n = 3).
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favored (ΔG  =  −37.94  kJ/mol). Additionally, a similar 
value of Gibbs free energy was reported in our previous 
study of an amino acid pairing peptide C6 [34]. CADY, 
a 20-residue secondary amphipathic peptide also encap-
sulated all the siRNA at molar ratio 15/1 and adopted 
helical secondary structure. Compared to GL1, CADY 
displayed even stronger binding affinity with siRNA (Kd: 
0.152E−7  M) [35]. Interestingly, CADY enters cells not 
through the endosomal pathway but GL1 does, which 
may lead to the difference in the efficiency of intracellular 
release of siRNA.
The size of GL1-siRNA complexes slightly decreased 
from 100 to 80  nm when increasing the molar ratio 
from 20/1 to 40/1 possibly due to stronger electrostatic 
repulsion at higher molar ratio. Moreover, GL1-siRNA 
complexes displayed positive surface charge at a molar 
ratio of 20/1 (~21 mV). At a molar ratio of 40/1, due to 
the addition of more cationic peptide, GL1-siRNA com-
plexes’ surface charge increased to 27  mV. Interestingly, 
GL1 adopted a higher content of helical structure upon 
interaction with siRNA, possibly due to the decrease of 
the charge repulsion between cationic amino acids after 
partial positive charge was neutralized by anionic siRNA. 
The positive surface charge and secondary structure 
change suggest that GL1 and siRNA form stable com-
plexes mainly through the intermolecular binding and 
electrostatic interaction, which was consistent with some 
reported CPPs [36]. These favourable physicochemi-
cal characteristics lead to the significant cellular uptake 
of Cy3-labeled siRNA (95%), which is higher than Lipo 
(87%) in a serum free environment. In the presence of 
serum, GL1-siRNA complexes exhibited negative charge. 
This is possibly because excess anionic serum protein 
neutralizes the positive surface charge of GL1-siRNA 
complexes and displays negative charge. Due to the 
serum effect, cellular uptake of GL1-siRNA complexes 
dropped to 85%, which is still comparable to Lipo. More-
over, GL1-siRNA complexes induced 49 or 40% GAPDH 
gene silencing with serum or without serum respectively, 
with minimal cytotoxicity. Taken together, our experi-
mental data strongly supported our hypothesis that the 
cationic peptide GL1 electrostatically complexes with the 
anionic siRNA to produce a positively charged complex 
that has sufficient stability to allow efficient intracellular 
delivery of siRNA and induce specific gene silencing effi-
ciency. Note that GL1 delivered higher amount of siRNA 
to cells than Lipo but induced lower gene silencing effi-
ciency than Lipo, possibly due to insufficient endoso-
mal release of siRNA. Further modifications of GL1 to 
enhance endosomal release are required.
Conclusions
In this study, we have investigated the physicochemi-
cal characteristics of the peptide GL1, and evaluated its 
siRNA delivery efficiency and cellular toxicity on the 
CHO-K1 cell line. The major conclusions include the 
following: GL1 could form complexes with siRNA cargo 
at molar ratio ~10/1 mainly via electrostatic interaction 
and hydrophobic interaction; GL1 could spontaneously 
condense siRNA to form spherical particles with sizes on 
the nanoscale (80–100  nm); GL1 adopted α-helical sec-
ondary structure and became more so upon interaction 
Figure 6 Gene silencing efficiency in vitro. Silencing of GAPDH gene 
in CHO-K1 cells was evaluated by quantitative real time polymerase 
chain reaction (qRT-PCR). GAPDH siRNA concentration was 50 nM. 
Lipo was the positive control, and scrambled siRNA was used as the 
negative control. Results are expressed as mean ± standard deviation 
(n = 3). *P value <0.05, the gene silencing efficiency at a molar ratio 
of 40/1 in a serum free environment is significantly different from the 
other treatments.
Figure 7 Cell viability results of CHO-K1 cells treated with naked 
Lipofectamine 2000 or GL1, and the complexes with siRNA (50 nM) at 
different molar ratios. NT non-treated, MR peptide/siRNA molar ratio, 
Lipo Lipofectamine 2000. Results are expressed as mean ± standard 
deviation (n = 3). *P value < 0.05, the cell viability after GL1 treatment 
is statistically significant than that after Lipo treatment.
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with siRNA molecules to form stable complexes; at molar 
ratio 40/1, GL1 achieved higher cellular uptake of Cy3-
labeled siRNA (95%) than Lipofectamine 2000 in serum 
free environment and retained the same level of uptake 
as Lipofectamine 2000 (84%) with the presence of serum; 
in all the studied molar ratios, GL1 achieved higher cel-
lular viability (>85%) compared to Lipofectamine 2000 
(~70%). Therefore, GL1 demonstrated the potential for 
future applications as a vector for siRNA delivery.
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